

RESEARCH

A probiotic mix partially protects against castration-induced bone loss in male mice

Lina Lawenius¹, Hannah Colldén¹, Karin Horkeby¹, Jianyao Wu¹, Louise Grahnemo¹, Liesbeth Vandenput^{1,2}, Claes Ohlsson¹ and Klara Sjögren¹

¹Sahlgrenska Osteoporosis Centre and Centre for Bone and Arthritis Research, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, University of Gothenburg, Gothenburg, Sweden

²Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia

Correspondence should be addressed to K Sjögren: Klara.Sjogren@medic.gu.se

Abstract

Studies in postmenopausal women and ovariectomized mice show that the probiotic mix *Lacticaseibacillus paracasei* DSM13434, *Lactiplantibacillus plantarum* DSM 15312 and DSM 15313 (*L. Mix*) can protect from bone loss caused by sex steroid deficiency. Whether probiotic bacteria can protect bone also in sex steroid-deficient males is less studied. We used the orchietomized mouse as a model for age-dependent bone loss caused by decreasing sex hormone levels in males. We treated 10-week-old male mice with either vehicle (veh) or *L. Mix* for 6 weeks, starting 2 weeks before orchietomy (orx) or sham surgery. Importantly, mice treated with *L. Mix* had a general increase in total body bone mineral density (BMD) and lean mass ($P \leq 0.05$) compared with veh-treated mice. Detailed computer tomography analysis of dissected bones showed increased trabecular BMD of the distal metaphyseal region of the femur in *L. Mix* compared to veh-treated orx mice (+8.0%, $P \leq 0.05$). In the vertebra, *L. Mix* treatment increased trabecular bone volume fraction BV/TV (+11.5%, $P \leq 0.05$) compared to veh in orx mice. Also, *L. Mix* increased the levels of short-chain fatty acids (SCFAs) such as propionate and acetate and important intermediates in SCFA synthesis such as succinate and lactate in the cecal content of male mice. In conclusion, *L. Mix* treatment resulted in a general increase in BMD in adult male mice and prevented trabecular bone loss in femur and vertebra of orx mice. These bone protective effects of *L. Mix* were associated with increased levels of SCFAs in the cecal content of male mice.

Key Words

- ▶ osteoporosis
- ▶ bone mass
- ▶ probiotic
- ▶ gut microbiome
- ▶ short-chain fatty acids

Journal of Endocrinology
(2022) **254**, 91–101

Introduction

Osteoporosis is a debilitating disease affecting one in two women and one in five men after 50 years of age (Sambrook & Cooper 2006). Both men and women lose bone in an age-dependent manner because of decreasing sex hormone levels. In women, the rapid bone loss occurring during and early after menopause contributes to the lower bone mass and higher risk of fractures in women compared with men. Probiotic bacteria can alter the composition of

the gut microbiota or its metabolic activity and thereby confer a health benefit to its host (Bron *et al.* 2011). We have previously demonstrated that a probiotic mixture of three lactobacilli (*L. Mix*) can prevent bone loss in ovariectomized (ovx) female mice and postmenopausal women (Ohlsson *et al.* 2014, 2021, Jansson *et al.* 2019). Normal aging in males will cause a decrease in sex hormone levels and bone mass, and hypogonadism is an important

risk factor for osteoporosis in men (Vanderschueren *et al.* 2014). Orchiectomy (orx) results in decreased bone mass in rodents as well as in humans (Stepan *et al.* 1989, Erben *et al.* 2000). Several studies have demonstrated beneficial effects of probiotics on bone mass also in male mice under various conditions, but to our knowledge, no study has investigated the effects of probiotics on bone in castrated male mice (McCabe *et al.* 2013, McCabe & Parameswaran 2018, Collins *et al.* 2019, Schepper *et al.* 2019a,b).

Probiotics can affect bone mass regulation through several possible mechanisms. Gut microbiota fermentation of dietary fiber produces short-chain fatty acids (SCFAs) that strengthens the gut barrier. SCFAs function as an energy source for intestinal epithelial cells, regulate host immune responses, promote anti-inflammatory regulatory T (Treg) cells and affect enteroendocrine cells that play an important role in host physiology by secreting hormones (Arpaia *et al.* 2013, Martin-Gallausiaux *et al.* 2021). Estrogen-deficient mice treated with SCFAs are protected against bone loss (Lucas *et al.* 2018). Not only in the liver but also in other tissues, androgens are conjugated and thereby deactivated by glucuronidation, which increases the water solubility of the compounds (Barbier & Belanger 2008). The glucuronidated androgens are then excreted in urine or via bile to the small intestine. We have earlier demonstrated that the gut microbiota is a major regulator of androgen metabolism in intestinal contents, but the effect of treatment with probiotics on androgen metabolism in the gut is unknown (Colliden *et al.* 2019).

In the present study, we evaluate the bone protective effect of *L. Mix* in orx mice as a model for osteoporosis in men.

Materials and methods

Mouse model and treatment

C57BL/6J male mice purchased from Charles River were housed in a standard animal facility under controlled temperature (22°C), photoperiod (12 h light:12 h darkness cycle), with free access to fresh water and pellet diet (Teklad diet 2016, Envigo). Teklad diet 2016 is a fixed formula diet containing 16% protein from plant sources. Teklad diet 2016 does not contain alfalfa or soybean meal, thus minimizing the occurrence of natural phytoestrogens that can interfere in studies of castration-induced bone loss. We made the decision to use the C57BL/6J mouse strain since we used this strain in earlier studies of the effect of probiotic bacteria on castration-induced bone loss and wanted to be able to compare the results (Ohlsson *et al.* 2014, 2021,

Lawenius *et al.* 2020, 2022). At 12 weeks of age, the mice were randomized into four groups ($n=13-15$) and subjected to orx or sham surgery under inhalation anesthesia with isoflurane (Baxter Medical AB, Kista, Sweden). The number of mice in each group was decided based on experience from earlier studies with similar treatments and parameters studied (Ohlsson *et al.* 2014, 2021, Lawenius *et al.* 2020, 2022). In these studies, we found small but consistent effects on the bone with the number of observations ranging from 8 to 15 per group. Mice were treated with either *Lactocaseibacillus paracasei* DSM13434, *Lactiplantibacillus plantarum* DSM 15312 and DSM 15313 (*L. Mix*) or vehicle (veh, maltodextrin) for 6 weeks starting 2 weeks before orx or sham surgery. The freeze-dried probiotic bacteria were given in the drinking water at a concentration of 10^9 colony-forming units (cfu)/mL and water bottles were changed daily. Vigorous shaking for 1–2 min dispersed the bacteria in the water. The survival of the bacteria in the water bottles was checked regularly, and after 24 h, the concentration dropped to 50%. The probiotic bacteria were provided by Probi AB (Lund, Sweden). At the end of the study, mice were anesthetized with Ketador/Dexdomitor (Richter Pharma/Orion Pharma), bled from the axillary vein, and thereafter killed by cervical dislocation. Blood was allowed to coagulate for at least 30 min at room temperature and centrifuged for 10 min, the serum was then collected and frozen. Tissues for RNA preparation and cecal contents were snap-frozen in liquid nitrogen. Bones were excised and fixed in 4% paraformaldehyde. The treatment allocation was blinded for the scientist doing the analyses but not for the scientist handling the mice. All experimental procedures involving animals were approved by the regional animal ethics committee in Gothenburg (ethics number 19/467).

Dual-energy X-ray absorptiometry (DXA)

Total body bone mineral density (BMD), fat percentage, and lean mass were analyzed using Faxitron UltraFocus dual-energy X-ray absorptiometry (DXA) (Faxitron Bioptics, Tuscon, AZ, USA). Mice were scanned using a X-ray energy of 40 kV and 0.28 mA for 2.53 s with a spatial resolution of 24 μm using 2 \times geometric magnification. Images were analyzed using the software VISION DXA software (Faxitron Bioptics).

Peripheral quantitative computed tomography (pQCT)

Peripheral quantitative CT (pQCT; XCT Research m, Stratec Medizintechnik GmbH, Germany) was used to analyze

the trabecular and cortical compartments of the femur, operating at a resolution of 70 μm (Windahl *et al.* 1999). Briefly, trabecular bone was analyzed in the metaphyseal region of the femur. The scan was positioned in the metaphysis at a distance corresponding to 3% of the total length of the femur from the distal growth plate and the trabecular bone region was defined by setting an inner area to 45% of the total cross-sectional area. The cortical bone was analyzed in the mid-diaphyseal region at 36% of the total length of the femur from the distal growth plate.

High-resolution microCT (μCT)

High-resolution μCT analyses were performed using Skyscan 1172 scanner (Bruker MicroCT, Aartselaar, Belgium) as previously described (Moverare-Skrtec *et al.* 2014). Briefly, the vertebra (L5) was imaged with an X-ray tube voltage of 50 kV, a current of 200 μA and a 0.5 mm aluminum filter. The scanning angular rotation was 180° and the angular increment was 0.70°. The voxel size was 6.54 μm isotropically. NRecon (version 1.6.9) was used to perform the reconstruction after the scans. The trabecular bone in the vertebral body caudal of the pedicles was selected for analysis within a conforming volume of interest (cortical bone excluded) commencing at a distance of 5 μm caudal of the lower end of the pedicles and extending a further longitudinal distance of 230 μm in the caudal direction.

Gene expression analysis

RNA from vertebral bodies (L3 and L6) was extracted using TriZol Reagent (Sigma) followed by RNeasy Mini QIAcube Kit (Qiagen). Real-time PCR analyses were run using StepOnePlus Real-Time PCR systems (Applied Biosystems). Predesigned probes for *Rankl* (*Tnfrsf11*, Mm00441908_m1), *Opg* (*Tnfrsf11b*, Mm00435452_m1), *Il-6* (Mm00446190_m1), *Runx2* (Mm00501580_m1), *Col1a1* (Mm00801666_g1), *Trap* (*Acp5*, Mm00475698_m1), *Ctsk* (Mm00484036_m1) and *Tnf α* (Mm00443258_m1) were used (Applied Biosystems). The mRNA abundance of each gene was calculated using the $\Delta\Delta\text{Ct}$ method, adjusted for expression of 18S rRNA (4310893E, Applied Biosystems) and presented as relative expression.

Flow cytometry

Bone marrow cells from one femur were isolated and erythrocytes were lysed using 0.83% ammonium chloride. Cells were stained with eBioscience™ Fixable Viability Dye eFluor™ 780 according to the manufacturer's

protocol (Invitrogen, ThermoFisher Scientific). Cells were extracellularly stained with anti-CD3-BV510 (Clone 17A2, Nordic BioSite AB, Täby, Sweden), anti-CD4-FITC (Clone RM4-5, Nordic BioSite AB) and anti-CD25-APC (Clone 3C7, BD, Franklin Lakes, NJ, USA). Cells were then fixed and permeabilized using the FoxP3 staining buffer kit (Invitrogen, ThermoFisher Scientific) and intracellularly stained with anti-Foxp3-PE (Clone FJK-16s, ThermoFisher Scientific) according to the manufacturer's instruction. Treg cells were defined as CD4+CD25+Foxp3+, and results are expressed as the frequency of live cells. Samples were run on BD FACSVerser (BD), and data were analyzed using FlowJo software (version 10.4.1).

Short-chain fatty acids

Cecal SCFAs were measured using gas chromatography coupled to mass spectrometry detection (GC-MS) as described previously (Wichmann *et al.* 2013). Briefly, approximately 20–100 mg of cecal content was mixed with internal standards, added to glass vials and freeze-dried. All samples were then acidified with HCl, and SCFAs were extracted with two rounds of diethyl ether extraction. The organic supernatant was collected, the derivatization agent N-tert-butyltrimethylsilyl-N-methyltrifluoroacetamide (Sigma-Aldrich) was added and samples were incubated at room temperature overnight. SCFAs were quantified with a gas chromatograph (Agilent Technologies 7890A) coupled with a mass spectrometer (Agilent Technologies 5975C). SCFA standards were obtained from Sigma-Aldrich.

Androgen analysis

Steroids were extracted, derivatized and measured as described previously (Nilsson *et al.* 2015, Collden *et al.* 2019). Briefly, cecal contents were weighed, added to PBS (PBS) and homogenized by shaking with a 5 mm steel bead in a TissueLyzer II for 5 min. Serum samples were measured volumetrically by pipetting and diluted with PBS. After the addition of isotope-labeled standards, sex steroids were extracted by liquid–liquid extraction, followed by solid-phase extraction. Derivatization was performed in two steps: oximation followed by esterification. Testosterone and dihydrotestosterone (DHT) were separated with gas chromatography and detected with electron capture negative chemical ionization by an Agilent 7000 triple quadrupole mass spectrometer (Agilent). All peaks were integrated using the MassHunter quantitative analysis workstation software from Agilent. The measured concentration was corrected for the amount of input

material (wet mass of intestinal contents or volume of serum). In serum, the lower level of quantification (LLOQ) was 8 pg/mL for testosterone and 2.5 pg/mL for DHT (Nilsson *et al.* 2015), and in cecum, the LLOQ was 40 pg/g for testosterone and 20 pg/g for DHT (Colliden *et al.* 2019). Values below the LLOQ were set to half of the LLOQ in order not to overestimate undetectable hormone levels.

Serum analyses

Enzyme immunoassay kits were used to measure the bone resorption marker collagen type I C-terminal telopeptides (CTX-1, Immunodiagnosics Systems, Herlev, Denmark) and the bone formation marker procollagen type I N-terminal propeptide (PINP, Immunodiagnosics Systems, Herlev, Denmark) in serum according to the manufacturer's directives.

Statistical analyses

GraphPad Prism was used for all statistical analyses. Results are presented as means \pm s.e.m. Our main analysis is the two-way ANOVA where we calculated the overall effect of treatment (Veh/L. Mix), surgical procedure (sham/orx) and their interaction. We then did a *post hoc* analysis to calculate the effect of L. Mix compared to veh treatment in sham and orx mice, respectively, using Sidak's *post hoc* test corrected for multiple comparisons. If we had an overall effect of L. Mix vs veh or an interaction effect in the two-way ANOVA, we performed the *post hoc* test to see if the effect was mainly

in the sham or the orx group or in both. When only two groups were compared, between-group differences were calculated using the two-tailed Student's *t*-test. $P \leq 0.05$ was considered significant. Normal distribution was analyzed using the Shapiro–Wilk test. If the sample distribution did not pass the normality test, values were normalized by log transformation before analysis.

Results

L. Mix treatment increased total body BMD and lean mass in male mice

We treated 10-week-old male mice with either veh or a mixture of three probiotic bacteria, *Lactocaseibacillus paracasei* DSM 13434, *Lactiplantibacillus plantarum* DSM 15312 and DSM 15313 (L. Mix) for 6 weeks, starting 2 weeks before orx or sham surgery (Fig. 1A). As expected, orx mice gained less body weight compared to sham mice (Fig. 1B and C). Interestingly, treatment with L. Mix resulted in a general increase in body weight (Fig. 1B and C). Body composition analysis with DXA and organ dissection at the end of the study demonstrated that orx mice have decreased fat percent and weight of gonadal fat compared to sham mice, but L. Mix treatment had no effect on these parameters (Fig. 2A and Supplementary Table 1, see section on supplementary materials given at the end of this article). Lean mass was decreased with orx, but treatment with L. Mix resulted in a general increase in lean mass (Fig. 2B).





Figure 1

Treatment of adult mice with a mixture of three lactobacilli strains resulted in an increase in body weight. Ten-week-old male mice were treated with either vehicle (veh) or a mixture of three lactobacilli (L. Mix) for 6 weeks, starting 2 weeks before orchietomy (orx) or sham surgery. Study protocol (A). Body weight (BW) curve (B). Values are given as mean \pm s.e.m. ($n = 13$ – 15). Body weight at the end of study (C). Symbols in the scatter plots represent individual mice and the bars indicate mean \pm s.e.m. The overall effects of treatment (Veh/L. Mix), surgical procedure (sham/orx) and their interaction were calculated using two-way ANOVA, NS, not significant.

**Figure 2**

L. Mix treatment increased total body BMD and lean mass in male mice. Ten-week-old male mice were treated with either vehicle (veh) or a mixture of three lactobacilli (*L. Mix*) for 6 weeks, starting 2 weeks before orchietomy (orx) or sham surgery. At the end of the experiment, mice were analyzed with whole-body DXA to measure (A) percentage of fat, (B) lean mass and (C) areal bone mineral density (BMD) of whole body. Symbols in the scatter plots represent individual mice and the bars indicate mean \pm s.e.m. ($n = 13-15$). The overall effects of treatment (Veh/*L. Mix*), surgical procedure (sham/orx) and their interaction were calculated using two-way ANOVA, NS, not significant. The effect of *L. Mix* compared to veh treatment in sham and orx mice, respectively, was calculated by Sidak's *post hoc* test to correct for multiple comparisons, $*P \leq 0.05$.

A substantial part of lean mass is muscle tissue, but the relative weights of the dissected muscles quadriceps and levator ani were not affected by *L. Mix* treatment (Supplementary Table 1). As expected, orx mice had a decrease in whole-body BMD (Fig. 2C). Importantly, mice treated with *L. Mix* had a general increase in whole-body BMD (Fig. 2C).


L. Mix treatment increased trabecular bone mass in orx mice

Detailed CT analysis of dissected bones showed increased trabecular BMD of the femur in *L. Mix* compared to veh-treated orx mice but no effect in cortical bone (Fig. 3A and B). In the vertebra, *L. Mix* treatment increased trabecular bone volume fraction (BV/TV) and trabecular number compared to veh treatment in orx mice (Fig. 3C, D and G). Treatment with *L. Mix* also resulted in a general decrease in trabecular separation in the vertebra (Fig. 3E and G). The effect of the *L. Mix* vs veh treatment expressed in percent, both in the Orx and veh group, for the main bone parameters is presented in Supplementary Table 2. The Tb BMD of the femur was $8.0 \pm 3.5\%$ higher in orx mice treated with *L. Mix* compared with veh ($P \leq 0.05$, Supplementary Table 2). In the vertebra, the BV/TV was $11.5 \pm 4.5\%$ higher in orx mice treated with *L. Mix* compared with veh ($P \leq 0.05$, Supplementary Table 2). For the sham groups, the increase was not statistically significant indicating that although the combined effect of *L. Mix* in the sham and orx group is statistically significant in the two-way ANOVA, the effect is more pronounced in the orx than in the sham group (Supplementary Table 2). Since *L. Mix* resulted in a general increase in body weight (Fig. 1B and C) and lean mass (Fig. 2B), we corrected femur trabecular

BMD and lumbar vertebra BV/TV for body weight. After correction for body weight, there is still a loss of trabecular bone in femur and vertebra with castration and only a tendency for a protective effect on trabecular bone with *L. Mix* (Supplementary Fig. 1). This indicates that *L. Mix* has an effect on the whole body including the bone. At the end of the study, we measured bone turnover markers in serum and both the formation marker PINP and the resorption marker CTX-1 were increased with orx but treatment with *L. Mix* had no effect (Supplementary Fig. 2A and B). We compared expression of genes important in bone mass regulation in the vertebra of orx mice and found that *L. Mix* treatment decreased the expression of the osteoclast promoting gene *Rankl* compared to veh treatment (Fig. 4A). However, other genes indicating osteoclast formation and activity (*Opg*, *Trap*, *Ctsk*), osteoblast formation (*Bglap*, *Col1 α 1*) and inflammation (*Il-6*, *Tnf α*) were not significantly changed by *L. Mix* treatment (Fig. 4B, C, D, E, F, G and H).

L. Mix treatment increased the SCFAs propionate and acetate in the gut

Probiotics have the capacity to ferment dietary fiber and produce bone protective SCFAs that can be absorbed by the host (Louis & Flint 2017, Lucas *et al.* 2018, Tyagi *et al.* 2018). A 6-week treatment with *L. Mix* increased the cecal content of the SCFAs propionate and acetate compared with veh, and a similar trend ($P = 0.16$) was observed for butyrate (Fig. 5A, B and C). Two important intermediates in SCFA synthesis are succinate and lactate. *L. Mix* increased succinate in orx but not in sham mice (Fig. 5D). *L. Mix* increased lactate and, similar to succinate, this effect was more pronounced in orx mice, supported by a significant interaction factor (Fig. 5E).

**Figure 3**

L. Mix treatment increased trabecular bone mass in orch mice. Ten-week-old male mice were treated with either vehicle (veh) or a mixture of three lactobacilli (*L. Mix*) for 6 weeks, starting 2 weeks before orchidectomy (orx) or sham surgery. At the end of the experiment, dissected femurs were analyzed with peripheral quantitative CT (pQCT) to measure (A) trabecular bone mineral density (Tb BMD) and (B) cortical area (Crt area). Dissected vertebral body (L5) were analyzed with high-resolution μ CT to measure (C) trabecular bone volume fraction (BV/TV), (D) trabecular thickness (Tb Th), (E) trabecular separation (Tb Sp) and (F) trabecular number (Tb N). Representative μ CT images of L5 with cortical bone were excluded (G). Symbols in the scatter plots represent individual mice and the bars indicate mean \pm s.e.m. ($n = 13-15$). The overall effects of treatment (Veh/*L. Mix*), surgical procedure (sham/orx) and their interaction were calculated using two-way ANOVA, NS, not significant. The effect of *L. Mix* compared to veh treatment in sham and orx mice respectively was calculated by Sidak's *post hoc* test to correct for multiple comparisons, ** $P \leq 0.01$ and * $P \leq 0.05$.

No effect of *L. Mix* treatment on sex steroid levels in serum or gut

We have earlier demonstrated that the gut microbiota is a major regulator of androgen metabolism in intestinal contents but there was no effect of *L. Mix*

treatment on testosterone or DHT in neither serum nor intestinal contents of cecum (Supplementary Table 3). As expected, testosterone and DHT in serum decreased markedly following orx confirming successful castration (Supplementary Table 3).





Figure 4

Gene expression in the vertebra of orx mice after treatment with L. Mix. Ten-week-old male mice were treated with either vehicle (veh) or a mixture of three lactobacilli (L. Mix) for 6 weeks, starting 2 weeks before orchietomy (orx) or sham surgery. Real-time PCR analysis of gene expression known to affect bone turnover in the vertebra (L3 and L6): receptor activator of nuclear factor- κ B ligand (*Rankl*, A), osteoprotegerin (*Opg*, B), interleukin 6 (*Il-6*, C), tartrate resistant acid phosphatase (*Trap*, D), cathepsin K (*Ctsk*, E), tumor necrosis factor α (*Tnfa*, F), bone gamma-carboxyglutamate protein (*Bglap*, G) and Collagen, type α 1 (*Col1 α 1*, H). Symbols in the scatter plots represent individual mice and the bars indicate mean \pm s.e.m. ($n = 13-15$). $*P \leq 0.05$ vs the orx veh group. Between-group differences were calculated using Student's t-test.

**Figure 5**

L. Mix treatment increased the SCFAs propionate and acetate in the gut. Ten-week-old male mice were treated with either vehicle (veh) or a mixture of three lactobacilli (*L. Mix*) for 6 weeks, starting 2 weeks before orchiectomy (orx) or sham surgery. At the end of the study, we measured cecal short-chain fatty acids (SCFAs) propionate (A), acetate (B), butyrate (C) and intermediates in SCFAs production succinate (D) and lactate (E). Symbols in the scatter plots represent individual mice and the bars indicate mean \pm S.E.M. ($n = 13-15$). The overall effects of treatment (Veh/*L. Mix*), surgical procedure (sham/orx) and their interaction were calculated using two-way ANOVA, NS, not significant. The effect of *L. Mix* compared to veh treatment in sham and orx mice, respectively, was calculated by Sidak's *post hoc* test to correct for multiple comparisons, $**P \leq 0.01$ and $*P \leq 0.05$.

No effect of *L. Mix* treatment on regulatory T-cells in bone marrow of male mice

Orx decreased the frequency of Treg cells in the bone marrow of male mice, similar to what we have previously observed in ovx female mice (Supplementary Fig. 3) (Ohlsson *et al.* 2014). Treatment with *L. Mix* had no effect on the frequency of Treg in bone marrow (Supplementary Fig. 3).

Discussion

We have previously demonstrated that *L. Mix* can prevent bone loss in ovx female mice and postmenopausal women. In the present study, we show for the first time that *L. Mix* treatment protects bone also in sex hormone-deficient male mice. We used the orx mouse as a model for male osteoporosis. We treated 10-week-old male mice with either veh or *L. Mix* for 6 weeks, starting 2 weeks before orx or sham surgery. *L. Mix* treatment resulted in a general increase of body weight, lean mass and BMD compared with veh in male mice. *L. Mix* protected trabecular bone in the femur and vertebra of orx mice but had no effect on cortical bone. The bone protective effects were associated with an increase in the SCFAs propionate and acetate and two important intermediates in SCFA synthesis, succinate and lactate, in the cecal content of male mice.

L. Mix. treatment resulted in a general increase in whole-body BMD in male mice, and detailed analysis showed that the effect was on the trabecular bone compartment both in the femur and the vertebra with a more pronounced effect in orx compared to sham mice. Two earlier studies showed

that *Limosilactobacillus reuteri* increased the trabecular bone mass in the femur and vertebra of gonadal intact male mice (McCabe *et al.* 2013, Collins *et al.* 2019). *L. reuteri* also has beneficial effects on bone in male mice with low bone mass due to glucocorticoid treatment, diabetes type 1 or long-term antibiotic treatment (Zhang *et al.* 2015, Schepper *et al.* 2019a,b). Antiretroviral agents can trigger a bone loss in human immunodeficiency virus patients, and in male mice, *Lactiseibacillus rhamnosus* GG attenuates bone loss induced by the antiretroviral agent tenofovir disoproxil fumarate (Liu *et al.* 2019). Together, these studies suggest that probiotic treatment may have beneficial effects on bone in male mice with various conditions of bone loss but the present study is the first demonstrating a bone protective effect in a male mouse model of low bone mass due to sex hormone deficiency. After correction for the increased body weight with *L. Mix*, there was only a tendency for a protective effect on the trabecular bone with *L. Mix*. One may speculate that the increased levels of SCFAs in the gut with *L. Mix* may have a general effect that is not specific to bone. SCFAs have several metabolic functions serving both as energy sources for the gut epithelial cells and contributing to gluconeogenesis in the liver that may cause anabolism (Louis & Flint 2017). In our earlier studies, when we treated ovariectomized female mice with *L. Mix*, we saw a protective effect on bone but no effect on body weight with *L. Mix* (Ohlsson *et al.* 2014, 2021). However, the effect of castration on body composition is completely different for male and female mice. Male mice lose weight with castration while female mice gain weight mainly as an effect of increased fat mass. To summarize, we have a protective effect of *L. Mix* on bone after castration in both female and male mice, but

in male mice, this is accompanied with a general increase in body weight with *L. Mix*. In the vertebra of orx mice, *L. Mix* decreased the expression of *Rankl*, which is a major promotor of osteoclastogenesis. This finding indicates that the effect of *L. Mix* may be mediated via reduced bone resorption but no effect on other osteoclastic genes or serum bone turnover markers was observed. Furthermore, the *P*-value was not corrected for multiple testing and a significance level of $P < 0.0062$ would be required if we had corrected for eight tests using the conservative Bonferroni correction method when measuring gene expression.

In the present study, we show for the first time that *L. Mix* treatment changes the metabolic capacity of the gut microbiota. *L. Mix* treatment increased the SCFAs propionate and acetate and two important intermediates in SCFAs synthesis succinate and lactate in the cecal content of male mice. An earlier study in ovx mice showed that both feeding of a high fiber diet and treatment with SCFAs can protect from bone loss due to estrogen deficiency (Lucas *et al.* 2018). According to Lucas *et al.*, SCFAs in serum had a direct effect on osteoclastogenesis (Lucas *et al.* 2018). In the present study, we found decreased expression of *Rankl* in vertebra after treatment of orx mice with *L. Mix* suggesting decreased osteoclast activation. We found that orx decreased the frequency of Treg cells in bone marrow, similar to what we previously reported for ovx (Ohlsson *et al.* 2014). There was no effect of *L. Mix* on the frequency of Treg in bone marrow although there was a tendency for an increase in *L. Mix* compared to veh-treated orx mice. SCFAs are known to interact with immune cells in the gut and they can induce Treg cells and a more anti-inflammatory environment both in the gut and in peripheral organs (Arpaia *et al.* 2013, Furusawa *et al.* 2013, Smith *et al.* 2013). In a study by Tyagi *et al.*, treatment of female mice with the SCFA butyrate increased bone mass, and the effect was dependent on the induction of Treg cells (Tyagi *et al.* 2018). In *L. Mix*-treated orx mice, the tendency of an increased frequency of Treg cells in bone marrow may contribute to the protective effect of *L. Mix* on bone but this needs further investigation.

We showed in a previous study that the gut microbiota deconjugates androgens in cecum and that conventionally raised mice have high levels of testosterone and DHT in cecum and colon compared with mice raised in a sterile environment with no bacteria in the gut (Collden *et al.* 2019). High levels of deconjugated androgens in the gut may have implications for androgen-related diseases in the distal intestine, and changing the gut microbiota composition and/or metabolism by treatment with probiotics might modulate intestinal androgen

metabolism. Furthermore, in a study by Poutahidis *et al.*, the probiotic *L. reuteri*, when given to male mice from 5 until 12 months of age, could prevent age-related weight gain and increase the serum testosterone levels (Poutahidis *et al.* 2014). In the present study, treatment with *L. Mix* had no effect on the levels of testosterone or DHT in neither cecum nor serum of orx and sham mice. Compared with Poutahidis *et al.*, when other *L.* strains were used, the mice were younger and treated for a much shorter time (6 weeks).

To conclude, we show for the first time that *L. Mix* treatment protects trabecular bone in sex hormone-deficient male mice. The expression of *Rankl* was decreased in trabecular bone of orx mice indicating reduced osteoclast activation. *L. Mix* treatment changed the metabolic capacity of the gut microbiota, increasing the SCFAs propionate and acetate and two important intermediates in SCFAs synthesis succinate and lactate in the cecal content of male mice. One may speculate that *L. Mix* treatment increases bone mass via increased SCFA synthesis in male mice.

Supplementary materials

This is linked to the online version of the paper at <https://doi.org/10.1530/JOE-21-0408>.

Declaration of interest

C O and K S are listed as inventors on a patent application regarding the impact of probiotics on bone metabolism and K S has received research funding for probiotic-related research from Probi AB. The other authors have nothing to disclose.

Funding

This study was supported by the Swedish Research Council (grant number 2018-02589) and by grants from the Swedish state under the agreement between the Swedish government and the county councils (the ALF-agreement: 238261), the Lundberg Foundation (grant number 2017-0081), the Torsten Söderberg Foundation (grant number M65115), Probi AB and the Knut and Alice Wallenberg Foundation (grant number KAW 2015.0317).

Author contribution statement

Study design: L L, H C, L V, C O, and K S. Study conduct: L L, H C, K S. Data collection: L L, H C, K L G, J W, L G, L V, and K S. Data analysis: L L, H C, J W, L V, C O, and K S. Data interpretation: L L, H C, L V, C O, and K S. Drafting manuscript: L L, H C, C O and K S. Revising manuscript: L L, H C, C O and K S. Approving final version of manuscript: L L, H C, K L G, J W, L G, L V, C O, and K S. L L, H C, L V, C O and K S take responsibility for the integrity of the data analysis.

Acknowledgement

The authors would like to thank Anna Westerlund and Ulrika Björklund for excellent technical assistance. The SCFA were measured at BioMS Swedish National Infrastructure for Biological Mass Spectrometry funded by the Swedish Research Council.

References

- Arpaia N, Campbell C, Fan X, Dikly S, van der Veecken J, deRoos P, Liu H, Cross JR, Pfeffer K, Coffey PJ, *et al.* 2013 Metabolites produced by commensal bacteria promote peripheral regulatory T-cell generation. *Nature* **504** 451–455. (<https://doi.org/10.1038/nature12726>)
- Barbier O & Belanger A 2008 Inactivation of androgens by UDP-glucuronosyltransferases in the human prostate. *Best Practice and Research: Clinical Endocrinology and Metabolism* **22** 259–270. (<https://doi.org/10.1016/j.beem.2008.01.001>)
- Bron PA, van Baarlen P & Kleerebezem M 2011 Emerging molecular insights into the interaction between probiotics and the host intestinal mucosa. *Nature Reviews: Microbiology* **10** 66–78. (<https://doi.org/10.1038/nrmicro2690>)
- Colliden H, Landin A, Wallenius V, Elebring E, Fandriks L, Nilsson ME, Ryberg H, Poutanen M, Sjogren K, Vandenput L, *et al.* 2019 The gut microbiota is a major regulator of androgen metabolism in intestinal contents. *American Journal of Physiology: Endocrinology and Metabolism* **317** E1182–E1192. (<https://doi.org/10.1152/ajpendo.00338.2019>)
- Collins FL, Rios-Arce ND, Schepper JD, Jones AD, Schaefer L, Britton RA, McCabe LR & Parameswaran N 2019 Beneficial effects of *Lactobacillus reuteri* 6475 on bone density in male mice is dependent on lymphocytes. *Scientific Reports* **9** 14708. (<https://doi.org/10.1038/s41598-019-51293-8>)
- Erben RG, Eberle J, Stahr K & Goldberg M 2000 Androgen deficiency induces high turnover osteopenia in aged male rats: a sequential histomorphometric study. *Journal of Bone and Mineral Research* **15** 1085–1098. (<https://doi.org/10.1359/jbmr.2000.15.6.1085>)
- Furusawa Y, Obata Y, Fukuda S, Endo TA, Nakato G, Takahashi D, Nakanishi Y, Uetake C, Kato K, Kato T, *et al.* 2013 Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. *Nature* **504** 446–450. (<https://doi.org/10.1038/nature12721>)
- Jansson P, Curiaic D, Lazou Ahrén I, Hansson F, Martinsson Niskanen T, Sjögren K & Ohlsson C 2019 Probiotic treatment using a mix of three *Lactobacillus* strains for lumbar spine bone loss in postmenopausal women: a randomised, double-blind, placebo-controlled, multicentre trial. *Lancet Rheumatology* **1** e154–e162. ([https://doi.org/10.1016/S2665-9913\(19\)30068-2](https://doi.org/10.1016/S2665-9913(19)30068-2))
- Lawenius L, Scheffler JM, Gustafsson KL, Henning P, Nilsson KH, Colliden H, Islander U, Plovier H, Cani PD, de Vos WM, *et al.* 2020 Pasteurized *Akkermansia muciniphila* protects from fat mass gain but not from bone loss. *American Journal of Physiology: Endocrinology and Metabolism* **318** E480–E491. (<https://doi.org/10.1152/ajpendo.00425.2019>)
- Lawenius L, Gustafsson KL, Wu J, Nilsson KH, Moverare-Skrtic S, Schott EM, Soto-Giron MJ, Toledo GV, Sjogren K & Ohlsson C 2022 Development of a synbiotic that protects against ovariectomy induced trabecular bone loss. *American Journal of Physiology: Endocrinology and Metabolism* **322** E344–E354. (<https://doi.org/10.1152/ajpendo.00366.2021>)
- Liu H, Gu R, Li W, Zhou W, Cong Z, Xue J, Liu Y, Wei Q & Zhou Y 2019 *Lactobacillus rhamnosus* GG attenuates tenofovir disoproxil fumarate-induced bone loss in male mice via gut-microbiota-dependent anti-inflammation. *Therapeutic Advances in Chronic Disease* **10** 2040622319860653. (<https://doi.org/10.1177/2040622319860653>)
- Louis P & Flint HJ 2017 Formation of propionate and butyrate by the human colonic microbiota. *Environmental Microbiology* **19** 29–41. (<https://doi.org/10.1111/1462-2920.13589>)
- Lucas S, Omata Y, Hofmann J, Bottcher M, Iljazovic A, Sarter K, Albrecht O, Schulz O, Krishnacoumar B, Kronke G, *et al.* 2018 Short-chain fatty acids regulate systemic bone mass and protect from pathological bone loss. *Nature Communications* **9** 55. (<https://doi.org/10.1038/s41467-017-02490-4>)
- Martin-Gallausiaux C, Marinelli L, Blottiere HM, Larraufie P & Lapaque N 2021 SCFA: mechanisms and functional importance in the gut. *Proceedings of the Nutrition Society* **80** 37–49. (<https://doi.org/10.1017/S0029665120006916>)
- McCabe LR & Parameswaran N 2018 Advances in probiotic regulation of bone and mineral metabolism. *Calcified Tissue International* **102** 480–488. (<https://doi.org/10.1007/s00223-018-0403-7>)
- McCabe LR, Irwin R, Schaefer L & Britton RA 2013 Probiotic use decreases intestinal inflammation and increases bone density in healthy male but not female mice. *Journal of Cellular Physiology* **228** 1793–1798. (<https://doi.org/10.1002/jcp.24340>)
- Moverare-Skrtic S, Henning P, Liu X, Nagano K, Saito H, Borjesson AE, Sjogren K, Windahl SH, Farman H, Kindlund B, *et al.* 2014 Osteoblast-derived WNT16 represses osteoclastogenesis and prevents cortical bone fragility fractures. *Nature Medicine* **20** 1279–1288. (<https://doi.org/10.1038/nm.3654>)
- Nilsson ME, Vandenput L, Tivesten Å, Norlen AK, Lagerquist MK, Windahl SH, Borjesson AE, Farman HH, Poutanen M, Benrick A, *et al.* 2015 Measurement of a comprehensive sex steroid profile in rodent serum by high-sensitive gas chromatography-tandem mass spectrometry. *Endocrinology* **156** 2492–2502. (<https://doi.org/10.1210/en.2014-1890>)
- Ohlsson C, Engdahl C, Fak F, Andersson A, Windahl SH, Farman HH, Moverare-Skrtic S, Islander U & Sjogren K 2014 Probiotics protect mice from ovariectomy-induced cortical bone loss. *PLoS ONE* **9** e92368. (<https://doi.org/10.1371/journal.pone.0092368>)
- Ohlsson C, Lawenius L, Andersson A, Gustafsson KL, Wu J, Lagerquist MK, Moverare-Skrtic S, Islander U & Sjogren K 2021 Mild stimulatory effect of a probiotic mix on bone mass when treatment is initiated 1.5 weeks after ovariectomy in mice. *American Journal of Physiology: Endocrinology and Metabolism* **320** E591–E597. (<https://doi.org/10.1152/ajpendo.00412.2020>)
- Poutahidit S, Springer A, Levkovich T, Qi P, Varian BJ, Lakritz JR, Ibrahim YM, Chatzigiagos A, Alm EJ & Erdman SE 2014 Probiotic microbes sustain youthful serum testosterone levels and testicular size in aging mice. *PLoS ONE* **9** e84877. (<https://doi.org/10.1371/journal.pone.0084877>)
- Sambrook P & Cooper C 2006 Osteoporosis. *Lancet* **367** 2010–2018. ([https://doi.org/10.1016/S0140-6736\(06\)68891-0](https://doi.org/10.1016/S0140-6736(06)68891-0))
- Schepper JD, Collins FL, Rios-Arce ND, Raetz S, Schaefer L, Gardinier JD, Britton RA, Parameswaran N & McCabe LR 2019a Probiotic *Lactobacillus reuteri* prevents postantibiotic bone loss by reducing intestinal dysbiosis and preventing barrier disruption. *Journal of Bone and Mineral Research* **34** 681–698. (<https://doi.org/10.1002/jbmr.3635>)
- Schepper JD, Collins F, Rios-Arce ND, Kang HJ, Schaefer L, Gardinier JD, Raghuvanshi R, Quinn RA, Britton R, Parameswaran N, *et al.* 2019b Involvement of the gut microbiota and barrier function in glucocorticoid induced osteoporosis. *Journal of Bone and Mineral Research* **35** 801–820. (<https://doi.org/10.1002/jbmr.3947>)
- Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, Bohlooly M, Glickman JN & Garrett WS 2013 The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. *Science* **341** 569–573. (<https://doi.org/10.1126/science.1241165>)
- Stepan JJ, Lachman M, Zverina J, Pacovsky V & Baylink DJ 1989 Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling. *Journal of Clinical Endocrinology and Metabolism* **69** 523–527. (<https://doi.org/10.1210/jcem-69-3-523>)
- Tyagi AM, Yu M, Darby TM, Vaccaro C, Li JY, Owens JA, Hsu E, Adams J, Weitzmann MN, Jones RM, *et al.* 2018 The microbial metabolite butyrate stimulates bone formation via T regulatory cell-mediated regulation of WNT10B expression. *Immunity* **49** 1116.e7–1131.e7. (<https://doi.org/10.1016/j.immuni.2018.10.013>)

- Vanderschueren D, Laurent MR, Claessens F, Gielen E, Lagerquist MK, Vandenput L, Borjesson AE & Ohlsson C 2014 Sex steroid actions in male bone. *Endocrine Reviews* **35** 906–960. (<https://doi.org/10.1210/er.2014-1024>)
- Wichmann A, Allahyar A, Greiner TU, Plovier H, Lunden GÖ, Larsson T, Drucker DJ, Delzenne NM, Cani PD & Backhed F 2013 Microbial modulation of energy availability in the colon regulates intestinal transit. *Cell Host and Microbe* **14** 582–590. (<https://doi.org/10.1016/j.chom.2013.09.012>)
- Windahl SH, Vidal O, Andersson G, Gustafsson JA & Ohlsson C 1999 Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. *Journal of Clinical Investigation* **104** 895–901. (<https://doi.org/10.1172/JCI6730>)
- Zhang J, Motyl KJ, Irwin R, MacDougald OA, Britton RA & McCabe LR 2015 Loss of bone and Wnt10b expression in male type 1 diabetic mice is blocked by the probiotic *Lactobacillus reuteri*. *Endocrinology* **156** 3169–3182. (<https://doi.org/10.1210/EN.2015-1308>)

Received in final form 23 May 2022

Accepted 30 May 2022

Accepted Manuscript published online 31 May 2022